No­var­tis sets eyes on new­ly-ac­quired Alex­ion with break­through tag for rare dis­ease hope­ful ip­ta­co­pan

For years, Alex­ion’s rare-dis­ease port­fo­lio that cen­tered on C5 in­hibitor Soliris has held its grip on a group of prof­itable ul­tra-rare in­di­ca­tions. But chal­lengers are look­ing to take the throne, in­clud­ing No­var­tis and its mid-stage can­di­date that has gar­nered in­ter­est from the FDA.

The FDA on Wednes­day slapped No­var­tis’ ip­ta­co­pan (LNP023) with its break­through tag to treat rare blood dis­or­der parox­ys­mal noc­tur­nal he­mo­glo­bin­uria (PNH), set­ting the drug up for a quick re­view and po­ten­tial chal­lenge to Alex­ion’s Soliris/Ul­tomiris block­buster fran­chise.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.